Prophylaxis Invasive Pneumococcal Diseases and Pneumonia Clinical Trial
Official title:
A Study to Evaluate the Safety, Reactogenicity & Immunogenicity of the GSK Biologicals Candidate Pneumococcal Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations, in Healthy Elderly Subjects
As the licensed Pneumovax 23™ vaccine is not always satisfactory in elderly subjects, the safety and the immune response of the new investigational pneumococcal protein vaccine is evaluated in healthy elderly population.
Since influenza vaccination is recommended in the age range of the study population, Fluarix™
(GlaxoSmithKline Biologicals) vaccine will be offered free of charge during the study period
(for 3 consecutive years starting from September 2004), to be used by Investigators according
to national vaccination schedule/practice.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
2007.
;